Singaporean Biotech Startup ImmunoScape Raises US$11M

ImmunoScape is currently collaborating with Arcturus Therapeutics which began human trials of potential COVID-19 vaccine yesterday

Singapore-based biotech startup ImmunoScape announced in a press release today that it has raised US$11 million (SG$14.8 million) in an equity financing round led by U.S.-based Anzu Partners, with participation from the University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.

The startup will use the fresh funds to hire additional personnel, including immunologists, bioinformaticians and specialists, for its laboratory at Singapore-based research and development hub Biopolis, Co-founder and CEO Choon Peng Ng told The Straits Times.

Peng also said that the startup is looking to expand into key markets such as the U.S. and Japan, and is building a business development team and lab in the U.S. as well.

ImmunoScape provides insights into the human immune system. Its immune profiling platform provides deep insights into the T-cells of the human immune system. The company is currently engaged in COVID-19 related projects across three continents, according to the press release.

The startup hopes to eventually use machine learning and artificial intelligence to uncover deeper insights into the human immune system.

“There is an urgent need to understand how the T-cell immune response contributes to COVID-19 immunity and can be leveraged for vaccine design,” said ImmunoScape Co-founder and COO Dr Alessandra Nardin.

“In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals,” he continued. “We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners.”

ImmunoScape is also collaborating with several vaccine development companies, including San Diego-based Arcturus which is running clinical trials in Singapore, and began human trials of potential COVID-19 vaccine yesterday.

“As a Singapore-based firm supported by the Agency for Science Technology and Research (ASTAR), our team has deep experience assessing T-cell immune response to dengue, hepatitis B, and other viruses,” Ng said. Ng was formerly a senior executive at ASTAR.

“It was clear that we must provide deep support to COVID-19 vaccine development in this global crisis,” he added.

ImmunoScape’s technology was based on work that began at Stanford University, and continued at A*STAR, where the company was established in 2017.

The company aspires to continue its efforts in enabling advanced immunotherapies for cancer, an area where its scientific track record is strong. The startup focuses on immuno-oncology research which aims at developing cancer treatments using the body’s immune system.

ImmunoScape has received support from ASTAR and its commercialization arm Accelerate, as well as Enterprise Singapore.

“In 2019 we co-authored a paper together with collaborators at Genentech illustrating the role of our technology in evaluating checkpoint blockade immunotherapies,” said Nardin.

“The interest in those insights attracted global attention and encouraged us to seek financing to expand further into the U.S. market,” he added.

“To deliver on the promise of individualized medicine for cancer, the biopharma industry desperately needs more insight into every patient’s unique immune system. ImmunoScape can deliver this, and we are delighted to support them,” Managing Partner at Anzu Partners, David Michael said.

“ImmunoScape’s technology can guide the development of immunotherapies, as the company has shown in major scientific journals. Now they are bringing these insights and capabilities to major biopharma clients globally,” Partner at UTEC, Dr Naonori Kurokawa said.

Header image by National Cancer Institute on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Monika Ghosh
Monika Ghosh is a Staff Writer at Jumpstart

RELATED POSTS

How the Metaverse Will Change the Future of Workspace

How the Metaverse Will Change the Future of Workspace

The metaverse—it’s not a sci-fi concept anymore! People are now working in virtual offices in the metaverse. It is a cloud-based, immersive social environment in which 3D avatars interact with one another. You could be on a beach in Thailand and still be able to attend that important meeting with your colleagues in the metaverse—work can take place wherever you are located.

What Is Over-The-Counter Stock Trading

What Is Over-The-Counter Stock Trading?

If you thought that you could only buy stocks from the stock market, you guessed wrong. Investors can also purchase stocks directly from the companies they wish to invest in. This is called over-the-counter (OTC) trading.

Top 5 Most Valuable Meme Coins of 2022

Top 5 Most Valuable Meme Coins of 2022

Billionaires, including Elon Musk and Mark Cuban, have waxed eloquent about meme coins. These are digital tokens that started as jokes but have since taken off in value. Some even credit meme coins for helping cryptocurrencies, in general, reach a larger audience.

The Butterfly Effect 3 Fascinating Businesses Stories

The Butterfly Effect: 3 Fascinating Businesses Stories

The butterfly effect, a part of chaos theory (a branch of mathematics and mechanics that studies random or unpredictable events in complex systems), is a phenomenon wherein a small or seemingly unrelated event sets in motion the trajectory of something significant. It is fascinating to observe this phenomenon, especially in the dynamic realm of businesses.